Login to Your Account

Financings Roundup

Glycomimetics Makes IPO Try; Sickle Cell Therapy In Phase II

By Randy Osborne
Staff Writer

Monday, October 7, 2013
Powered by a deal with Pfizer Inc., Glycomimetics Inc. is looking to solidify further its position in the race for therapies that would treat vaso-occlusive crises (VOCs) in sickle cell disease (SCD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription